HY07121 not checked

Sichuan Huiyu Pharmaceutical Co., Ltd · HY0007-101 · HY0007-SC-101

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“HY07121 should be administered intravenously at recommended dose.”In the company’s words, NCT06639256 on ClinicalTrials.gov
Tested for
Safety (2 trials), Tolerability (2 trials), Efficacy (2 trials)
Main trialPhase 1/2
“This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 in participants with advanced solid tumors.”In the company’s words, NCT06639256 on ClinicalTrials.gov
Other names
HY0007-101 · HY0007-SC-101

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 26 May 2027 Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors
Phase 1/2Not yet recruiting Apr 2028 Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow HY07121

Following is part of Solo: you see every change to HY07121 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in